ReviewMolecules (Basel, Switzerland)2020
The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Electric Method for the Desulfation of Polysaccharides From Red Microalgae (Porphyridium cruentum) Cultures.Biopolymers · 2026Article
- Unleashing the power of microalgae: a pioneering path to sustainability and achieving the sustainable development goals.Environmental science and pollution research international · 2025Review
- Exploring the Structural Diversity and Biotechnological Potential of the Rhodophyte Phycolectome.Marine drugs · 2024Review
- Oceanic Breakthroughs: Marine-Derived Innovations in Vaccination, Therapy, and Immune Health.Vaccines · 2024Review
- Antiviral Effect of MicroalgaeMarine drugs · 2024Article
- Quantification of Xylanolytic and Cellulolytic Activities of Fungal Strains Isolated fromMarine drugs · 2023Article
- Review
- Comparing the Ability of Secretory Signal Peptides for Heterologous Expression of Anti-Lipopolysaccharide Factor 3 inMarine drugs · 2023Article
- Edible microalgae: potential candidate for developing edible vaccines.Vegetos (Bareilly, India) · 2023Review
- Bioprospection of the trichomonacidal activity of lipid extracts derived from marine macroalgae Gigartina skottsbergii.PloS one · 2023Article
- Characterization ofInternational journal of environmental research and public health · 2022Article
- An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice.Pharmaceuticals (Basel, Switzerland) · 2022Article
- In silico evidence of antiviral activity against SARS-CoV-2 main protease of oligosaccharides from Porphyridium sp.The Science of the total environment · 2022Article
- Algae and Their Metabolites as Potential Bio-Pesticides.Microorganisms · 2022Review
- Genetic Engineering of Microalgae for Secondary Metabolite Production: Recent Developments, Challenges, and Future Prospects.Frontiers in bioengineering and biotechnology · 2022Review
- Can algae contribute to the war with Covid-19?Bioengineered · 2021Review
- Advanced Applications for Protein and Compounds from Microalgae.Plants (Basel, Switzerland) · 2021Review
- Antiviral Activity of Carrageenans and Processing Implications.Marine drugs · 2021Review
- Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis.Algal research · 2021Article
- Microalgae: therapeutic potentials and applications.Molecular biology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The emergence of the Coronavirus Disease 2019 (COVID-19) caused by the SARS-CoV-2 virus has led to an unprecedented pandemic, which demands urgent development of antiviral drugs and antibodies; as well as prophylactic approaches, namely vaccines. Algae biotechnology has much to offer in this scenario given the diversity of such organisms, which are a valuable source of antiviral and anti-inflammatory compounds that can also be used to produce vaccines and antibodies. Antivirals with possible activity against SARS-CoV-2 are summarized, based on previously reported activity against Coronaviruses or other enveloped or respiratory viruses. Moreover, the potential of algae-derived anti-inflammatory compounds to treat severe cases of COVID-19 is contemplated. The scenario of producing biopharmaceuticals in recombinant algae is presented and the cases of algae-made vaccines targeting viral diseases is highlighted as valuable references for the development of anti-SARS-CoV-2 vaccines. Successful cases in the production of functional antibodies are described. Perspectives on how specific algae species and genetic engineering techniques can be applied for the production of anti-viral compounds antibodies and vaccines against SARS-CoV-2 are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.